08:00 , Jan 30, 2012 |  BC Week In Review  |  Company News

Capstone Therapeutics dermatology, pulmonary news

Capstone said it will cease development of its two compounds, AZX100 and TP508, to preserve cash and move towards winding down operations since it has not yet found a partner for AZX100. The company also...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Capstone Therapeutics pulmonary, dermatology news

Capstone said it will reduce headcount by 14 (78%) to 4 to save cash while it searches for a partner for AZX100. The company will operate "virtually" by maintaining required regulatory and financial functions. The...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Clinical News

AzERx, Capstone Therapeutics preclinical data

In a mouse model of pulmonary fibrosis, once-daily aerosolized AZX100 for 28 days significantly reduced apoptosis across all cell types in the lung vs. untreated controls (p=0.00058). Capstone has exclusive rights to AZX100 from AzERx...
07:00 , May 2, 2011 |  BC Week In Review  |  Clinical News

AZX100: Final Phase IIa data

Final data from the double-blind Phase IIa OL-ASCAR-03 trial in 146 patients showed that 3 and 10 mg intradermal AZX100 administered 9 and 21 days following arthroscopic shoulder surgery missed the primary endpoint of significantly...
07:00 , May 2, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

BTG plc (LSE:BGC) gained 4.90p to 248.4p last week after FDA approved an NDA from Centocor Ortho Biotech Inc. for Zytiga abiraterone acetate in combination with prednisone to treat metastatic, castration-resistant prostate cancer (CRPC) in...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

AZX100: Interim Phase IIa data

Interim 7-month data from the ongoing, double-blind Phase IIa OL-ASCAR-03 trial in 150 patients showed that 3 mg AZX100 significantly improved scar total volume from baseline to 3 months and scar length from baseline to...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

AZX100: Phase IIa data

The double-blind Phase IIa OL-ASCAR-05 trial in 59 patients showed that AZX100 missed the primary endpoint of significantly improving POSAS scores from baseline to 12 months post surgery vs. placebo. Additionally, Capstone said the 1...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

AZX100: Phase IIa data

The double-blind Phase IIa OL-ASCAR-04 trial in 59 patients showed that AZX100 missed the primary endpoint of significantly improving POSAS scores from baseline to 12 months post surgery vs. placebo. Patients received 3 or 10...
01:46 , Dec 15, 2010 |  BC Extra  |  Clinical News

Capstone falls on AZX100 data

Capstone Therapeutics (NASDAQ:CAPS) fell $0.52 (50%) to $0.52 on Tuesday after reporting data from three Phase IIa trials of AZX100 in keloid and surgical scarring. The synthetic 24-amino acid peptide analog of heat shock protein...
07:00 , Jul 12, 2010 |  BC Week In Review  |  Clinical News

AZX100: Phase IIa ongoing

Capstone said it would continue a double-blind, placebo-controlled Phase IIa trial (OL-ASCAR-03) evaluating 3 and 10 mg AZX100 in 150 patients based on an independent statistician's interim analysis for safety and futility. The company has...